OncoMatch

OncoMatch/Clinical Trials/NCT07669298

Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer

Is NCT07669298 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for rectal cancer.

NARecruitingMedical University of GdanskNCT07669298Data as of Sep 2026Location: France · Poland
Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Excluded: MLH1 loss

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)

Excluded: MSH2 loss

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)

Excluded: MSH6 loss

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)

Excluded: PMS2 loss

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)

Excluded: MSI high

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)

Disease stage

Grade: poor histological differentiation (grade 3), high tumour budding (grade 2-3)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: pelvic radiation

Prior receipt of pelvic radiation

Lab requirements

Blood counts

ANC ≥ 1.5 × 10^9/L; Hb ≥ 8.0 g/dL (transfusions allowed); Platelet count ≥ 75 × 10^9/L

Kidney function

Serum creatinine clearance ≥ 50 mL/min (Cockcroft-Gault); Absence of significant proteinuria (<1 g/24 h if screening positive)

Liver function

Serum albumin ≥ 3.0 g/dL; Total bilirubin ≤ 2.0 mg/dL; AST ≤ 3 × ULN; ALT ≤ 3× ULN; ALP ≤ 3 × ULN

Adequate hematologic, liver, and renal function as per protocol laboratory criteria

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07669298 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior pelvic radiation disqualifies patients from enrollment.

Are patients with MLH1 alterations eligible?

No. MLH1 loss is an exclusion criterion.

Are patients with MSH2 alterations eligible?

No. MSH2 loss is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify